Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTXW | BCTX

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.


TSX:BCT - Post by User

Comment by LondonInveston May 12, 2022 2:52pm
139 Views
Post# 34678877

RE:BCTX To Quickly Regain $8/share

RE:BCTX To Quickly Regain $8/share
Well, that did not turn out at all how I imagined it.  I was able to add at these low levels today.  Still think there is really good returns possible here.  I am a holder of company.  Fast Track Designation is not just granted to anyone.  We will see where we are in a year.  These levels are insane.  Essentially at cash on hand levels now.  I think small cap biotech has between 25-33% of companies trading below cash on hand.  This has never happened... ever.  Silly levels, painful to experience, but it does not take away their pipeline, early success and FDA recognition of results significance.  GL
<< Previous
Bullboard Posts
Next >>